I bought my first shares, a whopping 20 shares, in July of 2010 for $18, buying with my sale of half my $DNDN stake at $50 (should have sold it all, but live and learn). I thought Provenge was leading a wave of autologous dendritic cell therapies and I was going to be in all of them -- which has led to some pain (yeah, $IMUC)
In the end I will have been right on "being in all of them" with my timing just being off (missed it by thiiisss much), but in the winter of 2026 I will have been invested heavily in the only two autologous dendritic cell immunotherapies approved for patients.